Scientists have re-engineered a well-known antibiotic to counter
drug resistance forming a new molecule in the process that could
assist in treating hospital infections, which were previously
resistant to common antibiotics putting...
Enanta Pharmaceuticals has announced the initiation of Phase 2
studies investigating a first in class antibiotic candidate that
treats community-acquired respiratory tract infections, which has
become the sixth most common cause of...
Acolyte Biomedica introduces a new platform for its MRSA test,
which promises to set the benchmark for laboratory-based screening
of the bacterium by confirming negatives in five hours and
positives within 24 hours.
The threat of antibiotic resistance reared its ugly head again
after US researchers found that the most common antibiotic
treatments do not work in a significant number of cases, leading
for calls to find viable alternatives to ageing,...
Scientists have described the cellular structure of a protein that
plays a critical role in drug resistance, which may open up new
avenues for laboratory research that may result in the enhancement
of existing therapies for Cancer...
Grunenthal has developed a novel method of delivering drugs to
children in the form of a drinking straw, which is set to provide a
solution to administering treatment to patients who cannot tolerate
unpleasant tasting drugs.
According to a new report, the emergence of antibacterial
resistance is set to push antibiotic R&D back into the
spotlight in an attempt to slow down the increasing levels of drug
resistance that could well erode the medical advances...
A new antibiotic that not only acts as a traditional antibiotic but
also acts on bacterial infections that have developed resistance to
existing types of antibiotic could herald the emergence of a new
tool to fight infections.
The Food and Drug Administration's (FDA) approval of the
first-in-class antibiotic, Tygacil (tigecycline), is set to provide
doctors with an alternative treatment for skin and intra-abdominal
infections that have previously been...
Researchers have discovered the structural basis for antibiotic
resistance to common pathogenic bacteria, which could herald the
design and development of a new class of antibiotic drugs.
Researchers at Harvard University in the US have developed a new
way of synthesising tetracyclines, potentially opening up avenues
to the development of new drugs in this valuable antibiotic class,
writes Phil Taylor.
Data from the first drug in a new class of antibiotics was
presented at this year's ECCMID conference, which showed the drug
demonstrated its efficacy against a wide variety of gram-positive
and gram-negative bacteria including...
According to a latest study, only half of all patients receive
appropriately administered antimicrobial infection medication
within one hour of major surgery. The figure emphasises just how
much patients are at risk from surgical...
Affinium Pharmaceuticals announced today it has selected a drug
candidate, which may represent a potential breakthrough as the
first antibiotic to a newly targeted bacterial pathway in 40 years.
High rates of antibiotic resistance in South and East Europe are
higher than in northern Europe because the regions have high rates
of antibiotic use, according to a study published in this week's
issue of The Lancet.
According to a recent survey, leading pharmaceutical firms claim
that despite the decline in R&D productivity, scientists are
working harder and completing more projects.
Researchers have identified a promising new drug target in their
fight against resilient Staphylococcus bacteria that can be
transmitted to patients in hospitals via contaminated medical
implants.
US peptide developers Helix BioMedix has entered into collaboration
with Smith & Nephew, which aims to focus on the development of
HB50, the company's lead topical anti-infective peptide.
Wyeth Pharmaceuticals has announced the submission of a global
registration dossier for its investigational antibiotic Tygacil
(tigecycline), a new class of treatment for intra-abdominal and
skin infections.
A new anti-infectives company, spun out of the Sanofi-Aventis
group, has received €40 million in financing from an international
group of leading life science investors led by Atlas Venture and
including Sofinnova, 3i, Abingworth...
The need for a new class of antibiotics to tackle the rising threat
of antibiotic resistance was the focus of a drug discovery
agreement between two UK companies. The deal aims to produce
broad-spectrum antibiotics that are urgently...
A new approach to outwit resistance to antibiotics has been
discovered by a team of researchers who hope to apply this
knowledge to form new strategies and targets to combat
drug-resistant bacteria ubiquitous in both hospital settings...
A laboratory test that is able to detect methicillin resistant
Staphylococcus aureus (MRSA) a day earlier then traditional
antimicrobial susceptibility testing (AST) gives fresh impetus to
treatment and infection control efforts that...
Sulfa drugs, the primary therapy for treating anthrax, are losing
the battle in its effectiveness in treating this bacterium, of
which antibiotic-resistant strains are emerging. Now,
computer-generated images which show bacterium...
Enanta Pharmaceuticals has announced the initiation of Phase 1
clinical trial of its new antibiotic candidate, EP-013420, a first
in its class Bridged Bicyclic Ketolide (BBK) antibiotic that could
prove effective against respiratory...
Scientists have discovered a highly effective method to produce
novel aminocoumarins, antibiotics that are useful in the fight
against drug-resistant bacteria that could represent a new
antibacterial class to tackle the growing problem...
Scientists may be fighting a losing battle to develop alternative
treatments to drug resistant pathogens, as research reveals the
evolution of drug resistance in bacteria is a trait that is
favoured through the process of natural...
A novel approach to treating tuberculosis (TB), focusing on a
potential drug target in the cell walls of Mycobacterium
tuberculosis, the bacterium that causes TB, a disease that is
reappearing as new, multiresistant drug-strains.
Pharmaceutical investment in antibiotic research and development
(R&D) must be reinvigorated so doctors have access to medicines
needed to combat the ever-growing threat of antibiotic resistant
infections.
The threat of emerging strains of bacteria with resistance to the
current arsenal of drugs was the subject of intense focus as the
14th Annual European Congress on Clinical Microbiology and
Infectious Diseases (ECCMID) got underway...
Although there are a number of interesting new compounds in the
antibacterial pipeline, none of them are likely to reach
blockbuster status, according to a new report from Datamonitor.
A team of researchers in Sweden have developed a drug based on a
naturally-occurring protein that could represent a new class of
antibacterial to tackle the growing problem of antibiotic
resistance.
Ipsat Therapies has completed a Phase I trial of a novel approach
to preventing bacterial resistance by de-activating antibiotics in
the gastrointestinal tract.
The market for antibacterial drugs is becoming increasingly
unattractive to major pharmaceutical companies, despite continued
strong worldwide demand for these products and the growing threat
of bacterial resistance, according to...
An Edinburgh-based marine biotech business has been given a £50,000
(€73 000) boost in its bid to scour tidal areas such as rock pools
to find and develop new drugs and antibiotics, including a new
compound found to be active against...
